Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by dt_coreon Mar 17, 2011 9:14pm

286 Views

Post# 18302435

RE: RE: RE: HEM = Top Pick

Sudden spike in price and volume on no news prompted an OSC request to disclose if any material non-public information was released. Accordingly HEM addressed this by commenting on what led to the intraday dramtic change in share price (which was the Top Pick recommendation on BNN).

It is common that the OSC would ask a company to comment on "unusual" intraday share price moves that have this kind of volume/price movement. HEM was not trying to do a pump and dump, just trying to address any concerns that something may have been leaked (which wasn't the case).

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!